Denali director receives RSU and option grants

Denali Therapeutics director Jennifer E. Cook received equity compensation consisting of restricted stock units and stock options.

Rhea-AI Filing Summary

Denali Therapeutics director Jennifer E. Cook received equity compensation consisting of restricted stock units and stock options. She acquired 6,408 shares of Common Stock at a price of $0.00 per share as a grant, bringing her direct Common Stock holdings to 32,483 shares.

Each of these 6,408 shares is represented by a restricted stock unit and a contingent right to receive one share of Common Stock, with 100% of the units vesting upon the earlier of the one-year anniversary of the grant date or the day preceding Denali’s next annual meeting of stockholders. She also received a stock option covering 19,226 shares of Common Stock at an exercise price of $19.66 per share, which will vest on the same schedule.

Insider Trade Summary

Grant/Award: 25,634 shares

Grant/Award 2 txns

Insider Cook Jennifer E.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	19,226	$0.00	$0.00
Grant/Award	Common Stock	6,408	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 19,226 contracts (Direct); Common Stock — 32,483 shares (Direct)

Footnotes (3)

1. F1. Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.
2. F2. Includes 6,408 unvested RSUs.
3. F3. 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.

Key Figures

RSU shares granted: 6,408 shares Post-grant common holdings: 32,483 shares Option shares granted: 19,226 shares +3 more

6 metrics

RSU shares granted 6,408 shares Restricted Stock Units representing Common Stock grant on June 3, 2026

Post-grant common holdings 32,483 shares Common Stock directly owned after RSU grant

Option shares granted 19,226 shares Stock option covering Common Stock granted on June 3, 2026

Option exercise price $19.66 per share Exercise price for 19,226-share stock option

RSU vesting trigger 1 year / pre-meeting Vests on one-year anniversary or day before next annual meeting

Option expiration June 3, 2036 Expiration date for stock option on Common Stock

Key Terms

Restricted Stock Unit ("RSU"), contingent right, vest, Stock Option (right to buy), +1 more

5 terms

Restricted Stock Unit ("RSU") financial

"Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock"

contingent right financial

"and a contingent right to receive one share of common stock of the Issuer"

vest financial

"100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

Stock Option (right to buy) financial

"Stock Option (right to buy) with an exercise price of 19.6600"

annual meeting of stockholders financial

"or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Denali Therapeutics (DNLI) director Jennifer Cook acquire in this Form 4?

Jennifer Cook received equity compensation grants, not open-market purchases. She acquired 6,408 shares of Common Stock through restricted stock units and a stock option covering 19,226 shares. These awards represent standard director compensation rather than discretionary trading activity.

How many Denali Therapeutics (DNLI) shares does Jennifer Cook hold after this grant?

After the grant, Jennifer Cook directly holds 32,483 shares of Denali Therapeutics Common Stock. This total includes 6,408 unvested restricted stock units that each represent a contingent right to receive one share when vesting conditions are satisfied under the award terms.

What are the terms of Jennifer Cook’s restricted stock units from Denali Therapeutics (DNLI)?

The grant consists of 6,408 restricted stock units, each tied to one share of Common Stock. One hundred percent of the units vest upon the earlier of the one-year anniversary of the grant date or the day preceding Denali’s next annual meeting of stockholders after the grant date.

What are the key details of the stock option granted to Jennifer Cook by Denali Therapeutics (DNLI)?

Jennifer Cook received a stock option for 19,226 shares of Common Stock with an exercise price of $19.66 per share. All option shares will vest upon the earlier of one year from the grant date or the day before Denali’s next annual meeting of stockholders following the grant.

Was Jennifer Cook’s Form 4 transaction in Denali Therapeutics (DNLI) a market buy or sell?

The Form 4 reflects compensation-related acquisitions, not market trades. Both the 6,408 restricted stock units and the 19,226-share stock option were granted to her at a price of $0.00 per share as equity awards for service, rather than open-market buying or selling.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/05/2026 - 04:43 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cook Jennifer E.

(Last) (First) (Middle)

C/O DENALI THERAPEUTICS INC.

161 OYSTER POINT BLVD.

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Denali Therapeutics Inc. [ DNLI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/03/2026		A		6,408(1)	A	$0	32,483(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$19.66	06/03/2026		A		19,226		(3)	06/03/2036	Common Stock	19,226	$0	19,226	D

Explanation of Responses:

1. Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.

2. Includes 6,408 unvested RSUs.

3. 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.

Remarks:

	/s/ Tyler Nielsen, by power of attorney	06/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)